diabetes mellitus type 1

Sotagliflozin NDA Submitted to FDA for Type 1 Diabetes

By March 26, 2018

Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.

Ozempic, Fiasp Now Available for the Treatment of Diabetes

By February 05, 2018

Both medications received approval from the FDA in 2017.

First Short-Acting Insulin Approved as a "Follow-On" Product

By December 11, 2017

The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.